| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratories of Immunology [Y. S., T. T., To. T.] and Chemotherapy [Ta. T., R. U., H. S., K. N.], Aichi Cancer Center Research Institute, Nagoya 464, Japan; Department of Internal Medicine, Aichi Cancer Center Hospital [T. H.], Nagoya 464, Japan; Departments of Internal Medicine I [Y. S., K. S.] and Pathology II [M. T.], Nagoya University School of Medicine, Nagoya 466, Japan; and Amgen, Inc. [K. M. Z.], Amgen Center, Thousand Oaks, California 91320
Accumulating evidence suggests that c-kit and its ligand, stem cell factor (SCF), play an important role in the regulation of at least three lineages of stem cell growth and possibly in leukemogenesis, while only limited data are available that suggest possible involvement of c-kit/SCF in the development of human solid tumors such as lung cancer. We have recently reported that c-kit is aberrantly expressed almost exclusively in small-cell lung cancer (SCLC) among various types of solid tumors. The present study revealed that c-kit protein ectopically expressed in SCLC is indistinguishable from that in leukemia cell lines with megakaryocy tic characteristics with respect to amount, molecular size, and autophosphorylation status in response to recombinant human SCF. Furthermore, significant chemotactic response as well as moderate in vitro cell growth was induced in SCLC cell lines by the addition of recombinant human SCF, suggesting that c-kit/SCF may play an important biological role in the development of SCLC. Our extensive search for activating mutations naturally occurring in the c-kit gene revealed an amino acid substitution in the transmembrane domain of an SCLC cell line, although the functional consequences of this variant allele are yet to be determined.
1 This work was supported in part by a Grant-in-Aid for the Comprehensive Ten-Year Strategy for Cancer Research from the Ministry of Health and Welfare, Japan; Grant-in-Aids for Cancer Research from the Ministry of Education, Science, and Culture and the Ministry of Health and Welfare, Japan; and by a grant from the Cancer Research Institute, Inc., New York.
2 To whom requests for reprints should be addressed, at Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Kanokoden, Chikusa-ku, Nagoya 464, Japan.
Received 10/ 5/92. Accepted 1/27/93.
This article has been cited by other articles:
![]() |
N. Rehfeld, H. Geddert, A. Atamna, H. E. Gabbert, U. Steidl, R. Fenk, R. Kronenwett, R. Haas, and U.-P. Rohr Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2232 - 2238. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakagawa, Y. Matsuno, H. Kunitoh, A. Maeshima, H. Asamura, and R. Tsuchiya Immunohistochemical KIT (CD117) Expression in Thymic Epithelial Tumors Chest, July 1, 2005; 128(1): 140 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, B. Weinkauf, J. Duyster, C. Peschel, C. J. Kirkpatrick, M. Theobald, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia Blood, May 15, 2004; 103(10): 3644 - 3654. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, M. O. Kowalski, D. Sayles, S. Dimitrijevic, C. Fletcher, et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5880 - 5887. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M.-S. Tsao, and F. A. Shepherd Expression and Prognostic Significance of Kit, Protein Kinase B, and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2241 - 2247. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Scotlandi, M. C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, et al. c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions J. Clin. Oncol., May 15, 2003; 21(10): 1952 - 1960. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al. Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications Clin. Cancer Res., January 1, 2003; 9(1): 188 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kijima, G. Maulik, P. C. Ma, E. V. Tibaldi, R. E. Turner, B. Rollins, M. Sattler, B. E. Johnson, and R. Salgia Regulation of Cellular Proliferation, Cytoskeletal Function, and Signal Transduction through CXCR4 and c-Kit in Small Cell Lung Cancer Cells Cancer Res., November 1, 2002; 62(21): 6304 - 6311. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Krystal, G. Sulanke, and J. Litz Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. McDoniels-Silvers, C. F. Nimri, G. D. Stoner, R. A. Lubet, and M. You Differential Gene Expression in Human Lung Adenocarcinomas and Squamous Cell Carcinomas Clin. Cancer Res., April 1, 2002; 8(4): 1127 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies J. Clin. Oncol., March 15, 2002; 20(6): 1692 - 1703. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G. P. Bagnara, et al. The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit Am. J. Pathol., December 1, 2000; 157(6): 2123 - 2131. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326. [Abstract] [Full Text] |
||||
![]() |
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood, August 1, 2000; 96(3): 925 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bondzi, J. Litz, P. Dent, and G. W. Krystal Src Family Kinase Activity Is Required for Kit-mediated Mitogen-activated Protein (MAP) Kinase Activation, However Loss of Functional Retinoblastoma Protein Makes MAP Kinase Activation Unnecessary for Growth of Small Cell Lung Cancer Cells Cell Growth Differ., June 1, 2000; 11(6): 305 - 314. [Abstract] [Full Text] |
||||
![]() |
K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Kim and H. E. Broxmeyer In Vitro Behavior of Hematopoietic Progenitor Cells Under the Influence of Chemoattractants: Stromal Cell-Derived Factor-1, Steel Factor, and the Bone Marrow Environment Blood, January 1, 1998; 91(1): 100 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Wehrle-Haller and J. Weston Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway Development, January 3, 1995; 121(3): 731 - 742. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |